Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07178743 · ClinicalTrials.gov registry record
Emulation of the PALOMA-2 Trial
A clinical trial of Advanced Breast Cancer, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- 6,097
- Enrollment target
- 1
- Study location
NCT07178743 is a study of Advanced Breast Cancer that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 6,097 participants, above the 247-participant average among 28 other Advanced Breast Cancer trials with a reported enrollment target (2368% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07178743, a study of Advanced Breast Cancer, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 6,097 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions Studied
Interventions
- DRUG Initiation of palbociclib plus letrozole
- DRUG Initiation of letrozole
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,097 participants |
| Start Date | 2025-07-14 |
| Est. Completion | 2026-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07178743
The ClinicalTrials.gov registry entry for NCT07178743 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 6,097 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 247-participant average among 28 other Advanced Breast Cancer trials with a reported enrollment target (2368% higher). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Initiation of palbociclib plus letrozole is the first listed.
NCT07178743 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07178743 about?
NCT07178743 is a clinical study titled "Emulation of the PALOMA-2 Trial". Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such s...
What is the current status of trial NCT07178743?
This trial is currently active not recruiting. The enrollment target is 6,097 participants. The study started on 2025-07-14. Estimated completion is 2026-03.
What conditions does trial NCT07178743 study?
This clinical trial studies the following conditions: Advanced Breast Cancer.
What interventions are being tested in trial NCT07178743?
The interventions under investigation include: Initiation of palbociclib plus letrozole (DRUG), Initiation of letrozole (DRUG).
Who is sponsoring clinical trial NCT07178743?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07178743 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Engage Psychosocial Intervention for Cancer Symptoms
RECRUITING · NA
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.